Amatuximab clinical trials
Also written MORAb-009.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How each study uses amatuximab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2011 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 2 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 1
Morphotek (5) · Eisai Co., Ltd. (1) · National Cancer Institute (NCI) (1)
Studies
Open first, then newest update. How each study uses amatuximab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural MesotheliomaCompletedPhase 2MorphotekNCT00738582Written as MORAb-009 (Amatuximab)How we know
- Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)TerminatedPhase 2MorphotekNCT02357147Written as AmatuximabHow we know
- Amatuximab for High Mesothelin CancersTerminatedEarly Phase 1National Cancer Institute (NCI)NCT01413451Written as Amatuximab (MORab-009)How we know
- A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing CancersCompletedPhase 1MorphotekNCT01521325Written as AmatuximabHow we know
- A Study of MORAb-009 in Patients With Solid TumorCompletedPhase 1Eisai Co., Ltd.NCT01018784Written as MORAb-009How we know
- An Efficacy Study of MORAb-009 in Subjects With Pancreatic CancerCompletedPhase 2MorphotekNCT00570713Written as MORAb-009How we know
- A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung CancerCompletedPhase 1MorphotekNCT00325494Written as MORAb-009How we know
Codes
What other systems call amatuximab · ClinicalTrials.gg INT005219
- MeSH (NLM) C526187amatuximabOne source NLM
- UNII (FDA) 6HP0354G04AMATUXIMABConfirmed FDA, NLM, Wikidata
- Wikidata Q4740637AmatuximabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C62483AmatuximabOne source FDA
- DrugBank DB12845One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C526187 | amatuximab | One source NLM |
| UNII (FDA) | 6HP0354G04 | AMATUXIMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q4740637 | Amatuximab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C62483 | Amatuximab | One source FDA |
| DrugBank | DB12845 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.